[Featured Stock] Ilyang Pharmaceutical Rises on Expansion to 29 Clinical Sites for COVID-19 Treatment 'Suppect'

[Asia Economy Reporter Minwoo Lee] Ilyang Pharmaceutical's stock price is on the rise. The news that the clinical trial institutions for 'Suppect,' a new coronavirus disease (COVID-19) treatment, have been expanded appears to have acted as a positive factor.

As of 10:34 a.m. on the 23rd, Ilyang Pharmaceutical's stock price recorded 101,000 KRW, up 4.45% from the previous day. The news of the expanded clinical trials for the COVID-19 treatment 'Suppect' under development seems to have had a positive effect.

According to the industry, the Russian Ministry of Health approved Phase 3 clinical trials administering Ilyang Pharmaceutical's chronic myeloid leukemia treatment 'Suppect' to COVID-19 patients at 11 medical institutions in Russia and Belarus in May. Recently, the number of target medical institutions has reportedly increased to 29, with 180 patients.

However, the industry still attaches the label of being exclusive to Russia. Since the clinical trials are conducted in Russia rather than the United States or Europe, there are concerns about the reliability.

This content was produced with the assistance of AI translation services.